Review of Systemic Immunosuppression for Autoimmune Uveitis

Ophthalmology and Therapy

Volumn 3, Issue 1-2, 2014, Pages 17-36

  Castiblanco, Claudia ^a   Foster, C Stephen ^a,b  

^a MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Corticosteroid; Immunomodulatory therapy; Inflammation; Ophthalmology; Uveitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; DEXAMETHASONE; DIFLUPREDNATE; ETANERCEPT; FLUOCINOLONE ACETONIDE; IMMUNOGLOBULIN; INFLIXIMAB; INTERFERON; LOTEPREDNOL; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE ACETATE; RAPAMYCIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RIMEXOLONE; RITUXIMAB; TACROLIMUS; TOCILIZUMAB; TRIAMCINOLONE; VOCLOSPORIN;

AUTOIMMUNE UVEITIS; BEHCET DISEASE; DRUG ADMINISTRATION ROUTE; DRUG DOSAGE FORM; DRUG MECHANISM; EYE INFLAMMATION; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFLAMMATION; MACULAR EDEMA; MUCOUS MEMBRANE PEMPHIGOID; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY; PROTEIN SYNTHESIS; REVIEW; SCLERITIS; SIGNAL TRANSDUCTION; UVEITIS; VISUAL ACUITY;

EID: 84914670823     PISSN: 21938245     EISSN: 21936528     Source Type: Journal    
DOI: 10.1007/s40123-014-0023-x     Document Type: Review

References (84)

1. Lee FF, Foster CS. Pharmacotherapy of uveitis. Expert Opin Pharmacother. 2010;11(7):1135–46.
2. Foster CS, Vitale AT. Diagnosis and treatment of uveitis. 2nd ed. New Delhi: Jaypee Brothers Medical Publishers; 2013.
3. Novack GD, Howes J, Crockett RS, Sherwood MB. Change in intraocular pressure during long term use of loteprednol etabonate. J Glaucoma. 1998;7(4):266–9.
4. Foster CS, Davanzo R, Flynn TE, Mcleod K, Vogel R, Crockett RS. Durezol (Difluprednate Ophthalmic Emulsion 0.05%) compared with Pred Forte 1% ophthalmic suspension in the treatment of endogenous anterior uveitis. J Ocul Pharmacol Therapy. 2010;26(5):475–83.
5. Siddique SS, Shah R, Suelves A, Foster CS. Road to remission: a comprehensive review of therapy in uveitis. Expert Opin Investig Drugs. 2011;20(11):1497–515.
6. Jaffe GJ, Martin DM, Callahan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four week results of a multicenter randomized clinic study. Ophthalmology. 2006;113:1020–7.
7. Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Writing Committee, Kempen JH, Altaweel MM, Holbrook JT, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior and panuveitis: the Multicenter Uvetis Steroid Treatment trial. Ophthalmology. 2011;119:1916–26.
8. Pavesio C, Zierhut M, Bairi K, et al. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in non-infectious posterior uveitis. Ophthalmology. 2010;117:567–75.
9. Arcinue CA, Cerón OM, Foster CS. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis. J Ocul Pharmacol Ther. 2013;29(5):501–7.
10. Jabs DA, Rosenbaum JT, Foster CS. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492–513.
11. Huang JJ, Gaudio PA. Ocular inflammatory disease and uveitis manual: diagnosis and treatment. Baltimore: Lippincott Williams & Wilkins; 2010.
12. Okada AA. Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm. 2005;13(5):335–51.
13. Daniel E, Thorne JE, Newcomb CW, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010;149(3):423–32.
14. Kempen JH, Daniel E, Dunn JP, et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ. 2009;339:2480.
15. Pasadhika S, Kempen JH, Newcomb CW, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009;148(500–509):e502.
16. Palestine AB, Nussenblatt RB, Gelato M. Therapy for human autoimmune uveitis with low dose cyclosporine plus bromocriptine. Transplant Proc. 1988;20:131–5.
17. Murphy CC, Greiner K, Plskova J, et al. Cyclosporine vs. tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol. 2005;123:634–41.
18. Hogan A, McAvoy C, Dick A, Lee R. Long term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology. 2007;11495:1000–6.
19. Shanmuganathan VA, Casely EM, Raj D, et al. The efficacy of sirolimus in the treatment of patients with refractory uveitis. Br J Ophthalmol. 2005;89(6):66–669.
20. Nguyen QD, Ibrahim MA, Watters A, Bittencourt M, Yohannan J, Sepah YJ, Dunn JP, Naor J, Shams N, Shaikh O, Leder HA, Do DV. Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study. J Ophthalmic Inflamm Infect. 2013;3(1):32.
21. Anglade E, Aspeslet LJ, Weiss SL. A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin. Clin Ophthalmol. 2008;2(4):693–702.
22. Dugel P, et al. Voclosporin for noninfectious uveitis involving the posterior segment: new analyses of the LUMINATE phase 2/3 trials. Paper presented at: ARVO 2012, Ft. Lauderdale; 2012.
23. Brubaker R, Font RL, Sheperd EM. Granulomatous sclerouveitis. Regression of ocular lesions with cyclophosphamide and prednisone. Arch Ophthalmol. 1971;86(5):517–24.
24. Fauci AS, Doppman JL, Wolff SM. Cyclophosphamide-induced remissions in advanced polyarteritis nodosa. Am J Med. 1978;64(5):890–4.
25. Fosdick WM, Parsons JL, Hill DF. Long-term cyclophosphamide therapy in rheumatoid arthritis. Arthritis Rheum. 1968;11(2):151–61.
26. Hoang-Xaun T, Foster CS, Rice BA. Scleritis in relapsing polychondritis. Response to therapy. Ophthalmology. 1990;97(7):892–8.
27. Pujari SS, Kempen JH, Newcomb CW, et al. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology. 2010;117:356–65.
28. Suelves AM, Arcinue CA, Gonzalez-Martin JM, et al. Analysis of a novel protocol of pulsed intravenous cyclophosphamide for recalcitrant or sever ocular inflammatory disease. Ophthalmology. 2013;120:1201–9.
29. Mudun BA, Ergen A, Ipcioglu SU, et al. Short-term chlorambucil for refractory uveitis in Behcet’s disease. Ocul Inmmunol Inflamm. 2001;9(4):219–29.
30. Feldmann M, Brennan FM, Maini R. Cytokines in autoimmune disorders. Int Rev Immunol. 1998;17:217.
31. Foster CS, Tufail F, Waheed NK, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol. 2003;121(4):437–40.
32. Sfikakis PP. Behcet’s disease; a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis. 2002;61(Suppl 2):ii 51–3.
33. Diaz-Llopis M, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 2012;119:1575–81.
34. Mushtaq B, Saeed T, Situnayake RD, et al. Adalimumab for sight-threatening uveitis in Behcet’s disease. Eye. 2007;21(6):824–5.
35. Beister S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007;9:319–24.
36. Mansour AM. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007;91:274–6.
37. Guignard S, Gossec L, Salliot C, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis. 2006;65(12):1631–4.
38. Burmester GR, Mease P, Dijkmans BA, et al. Adalimumab safety and mortality rates from global clinical trials or six immune-mediated inflammatory diseases. Ann Rheum Dis. 2009;68(12):1863–9.
39. Triolo G, Vadala M, Accardo-Palumbo A, et al. Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behcet’s disease. Ann Rheum Dis. 2002;61(6):560–1.
40. Breban M, Vignon E, Claudepierre P, et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six month open label study. Rheumatology (Oxford). 2002;41(11):128–1285.
41. Mangge H, Heinzl B, Grubbauer HM, et al. Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis. Rheumatol Int. 2003;23(5):258–61.
42. Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003;48(8):2122–7.
43. Braun J, Brandt J, Listing J, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo controlled trial. Arhthritis Rheum. 2003;48(8):2224–33.
44. Okada AA, Goto H, Ohno S. Mochizuki Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol. 2012;130(5):592–8.
45. Gallagher M, Quinones K, Cervantes-Castaneda RA, et al. Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol. 2007;91(10):1341–4.
46. Bhat P, Castaneda-Cervantes RA, Doctor PP, et al. Intravenous daclizumab for recalcitrant ocular inflammatory disease. Graefes Arch Clin Exp Ophthalmol. 2009;247(5):687–92.
47. Kiss S, Ahmed M, Letko E, et al. Long-term follow-up in patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy. Ophthalmology. 2005;112(6):1066–71.
48. Sobrin L, Huang JJ, Christen W, et al. Daclizumab for treatment of birdshot chorioretinopathy. Arch Ophthalmol. 2008;126(2):186–91.
49. Nussenblatt RB, Peterson JS, Foster CS, et al. Initial evaluation of subcutaneous daclizumab for non-infectious uveitis: a multicenter non-comparative interventional case series. Ophthalmology. 2005;112(5):764–70.
50. Kobashigawa J, David K, Morris J, et al. Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporin and corticosteroids. Transplant Proc. 2005;37(2):1339.
51. Tappeiner C, Heinz C, Specker C, Heiligenhaus A. Rituximab as a treatment option for refractory endogenous anterior uveitis. Ophthalmic Res. 2007;39:184–6.
52. Onal S, Kazokoglu H, Koe A, et al. Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener’s granulomatosis. Ocul Immunol Inflamm. 2008;16(5):230–2.
53. Sadreddini S, Noshad H, Molaeefard M, et al. Treatment of retinal vasculitis in Behcet’s disease with rituximab. Mod Rheumatol. 2008;18(3):306–8.
54. Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology. 2010;117(5):861–9.
55. Kazatchkine M, Kaveri S. Immunomodulation of autoimmune and inflammatory disease with intravenous immunoglobulin. N Engl J Med. 2001;345(10):747–55.
56. Onal S, Foster CS, Ahmed AR. Efficacy of intravenous immunoglobulin treatment in refractory uveitis. Ocul Immunol Inflamm. 2006;14:367–74.
57. Seider N, Beiran I, Scharf J, et al. Intravenous immunoglobulin therapy for resistant ocular Behcet’s disease. Br J Ophthalmol. 2001;85:1287–8.
58. Rosenbaum JT, George R, Gordon C. The treatment of refractory uveitis with intravenous immunoglobulin. Am J Ophthalmol. 1999;127(5):545–9.
59. Sekul E, Cupler E, Dalakas M. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. 1994;121:259–62.
60. Hayden FG. Antiviral agents (nonretroviral). In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill Professional; 2005. p. 1243–72.
61. Feron EJ, Rothova A, van Hagen PM, et al. Interferon-alpha 2b for refractory ocular Behcet’s disease. Lancet. 1994;343(8910):1428.
62. Kotter I, Vonthein R, Zierhut M, et al. Differential efficacy of human recombinant interferon-alpha-2a on ocular and extraocular manifestations of Behcet disease: results of an open 4-center trial. Semin Arthritis Rheum. 2004;33(5):320–35.
63. Mackensen F, Max R, Becker MD. Interferons and their potential treatment in ocular inflammation. Clin Ophthalmol. 2009;3:559–66.
64. Schafer J, Kjesbo N, Gleason P. Formulary review of 2 new biologic agents tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis. J Manag Care Pharm. 2010;16(6):402–16.
65. Brandao FM, Coelho P, Pinto P, Combe B. Tocilizumab—a new step in rheumatoid arthritis treatment. Acta Reumatol Port. 2010;35(3):302–12.
66. Patel A, Moreland L. Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of Tocilizumab therapy. Drug Design Dev Ther. 2010;4:263–78.
67. Goldback-Mansky R. Blocking Interleukin-1 in rheumatic diseases: its initial disappointments and recent successes in the treatment of autoinflammatory diseases. Ann NY Acad Sci. 2009;1182:111–23.
68. Gabay C, Lamacchia C, Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol. 2010;6:232–41.
69. Nigrovic PA, Mannion M, Prince FH. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63(2):545–55.
70. Bermas BL, Hill JA. Effects of immunosuppressive drugs during pregnancy. Arthritis Rheum. 1995;38:1722–32.
71. Schatz M, Patterson R, Zeitz S, et al. Corticosteroid therapy for the pregnant asthmatic patient. JAMA. 1975;233(804):807.
72. Alstead EM, Ritchie JK, Lennard-Jones JE, et al. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology. 1990;99:443–6.
73. Goldstein LH, Dolinsky G, Greenberg R, et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol. 2007;79:696–701.
74. Bar Oz B, Hackman R, Einarson T, et al. Pregnancy outcome after cyclosporine therapy during pregnancy; a meta-analysis. Transplantation. 2001;71:1051–5.
75. Ojeda-Uribe M, Gilliot C, Jung G, et al. Administration of rituximab during the first trimester of pregnancy without consequences for the newborn. J Perinatol. 2006;26:252–5.
76. Kim SY, Linton JM, Kolasinski SL. Successful treatment of new onset Wegener’s granulomatosis with IVIG (intravenous immunoglobulin) during pregnancy: a case report. Mod Rheumatol. 2008;18:177–80.
77. Friedman DM, Llanos C, Izmirly PM, et al. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum. 2010;62:1138–46.
78. Mancuso A, Ardita FV, Leonardi J, et al. Interferon alpha-2a therapy and pregnancy. Report of a case of chronic inflammatory demyelinating polyneuropathy. Acta Obstet Gynecol Scand. 1998;77:869–70.
79. Ozaslan E, Yilmaz R, Simsek H, et al. Interferon therapy for acute hepatitis C during pregnancy. Ann Pharmacother. 2002;36:1715–8.
80. Vantroyen B, Vanstraelen D. Management of essential thrombocythemia during pregnancy with aspiring, interferon alpha-2a and no treatment. A comparative analysis of the literature. Acta Haematol. 2002;107:158–69.
81. Lin P, Suhler EB, Rosenbaum JT. The future of uveitis treatment. Ophthalmology. 2014;121(1):365–76.
82. Lee YJ, Kim SW, Seo KY. Application for tacrolimus ointment in treating refractory inflammatory ocular surface diseases. Am J Ophthalmol. 2013;155:804–13.
83. Haghjou N, Soheilian M, Abdekhodaie MJ. Sustained release intraocular drug delivery devices for treatment of uveitis. J Ophthalmic Vis Res. 2011;6:317–29.
84. Foster CS, Nguyen QD. Uveitis subspecialty day. Session presented at 62nd American Academy of Ophthalmology, Chicago; 2012.